CXCL5 and breast carcinoma: These clinical data and our preclinical findings together suggest the potential of CXCL5 secretion induced by resistin-stimulated ADSCs in the breast tumor microenvironment, and that promoted breast cancer cell malignancy with the participation of ERK signaling pathway (Fig. 6F).